FDA Reviews Chantix On Safety Issue
Date: 20th November 2007
In the wake of adverse reports shown by the anti-smoking drug Chantix after being approved by the Food and Drugs Administration (FDA) for sale in the market, the drug monitoring agency has geared up to analyse data regarding safety issues concerning Chantix and has issued an early communication on Chantix safety. Especially FDA`s Center for Drug Evaluation and Research is analyzing the available information data and would forward the recommendations to the public once the analysis is properly completed.
The Food and Drugs Administration (FDA) approached the Chantix manufacturer Pfizer Incl. with regard to chantix usage showing adverse reactions on various occasions especially the appearance of suicidal thoughts due to Chantix administration. In a case report regarding an individual showing irregular behavior after using the anti-smoking drug Chantix, FDA has approached Pfizer for explanation and has asked reports on various similar occurrences in other people administering the medicine.
FDA has asked health care providers to supervise patients administering Chantix for mood changes and has also instructed patients to seek protection under medical care if they experience mood and behavior changes.
To help people in countering drowsiness due to Chantix usage FDA has asked them to adopt caution in operating and driving machinery till they come to know how the use of Chantix is impacting their behavior.